Cliff Asness's SRPT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.41 M shares of Sarepta Therapeutics, Inc. (SRPT) worth $26.4 M, representing 0.02% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in SRPT, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 1.28 M shares. Largest reduction occurred in Q3 2018, reducing 45,231 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Sarepta Therapeutics (SRPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sarepta Therapeutics (SRPT) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +34,648 | Add 0.00% | 34,647 | $25.80 |
| Q2 2013 | +30,374 | Add 0.00% | 30,373 | $38.06 |
| Q3 2013 | +16,115 | Add 53.06% | 46,488 | $47.24 |
| Q4 2013 | -14,488 | Reduce 31.17% | 32,000 | $20.38 |
| Q1 2014 | -32,000 | Sold Out | 32,000 | $0.00 |
| Q3 2015 | +17,075 | New Buy | 17,075 | $32.09 |
| Q4 2015 | +15,125 | Add 88.58% | 32,200 | $38.57 |
| Q1 2016 | -8,932 | Reduce 27.74% | 23,268 | $19.51 |
| Q2 2016 | -23,268 | Sold Out | 23,268 | $0.00 |
| Q3 2016 | +4,981 | New Buy | 4,981 | $61.43 |
| Q4 2016 | +36,738 | Add 737.56% | 41,719 | $27.42 |
| Q1 2017 | +10,648 | Add 25.52% | 52,367 | $29.60 |
| Q2 2017 | +501 | Add 0.96% | 52,868 | $33.71 |
| Q3 2017 | +28,600 | Add 54.10% | 81,468 | $45.36 |
| Q4 2017 | -9,368 | Reduce 11.50% | 72,100 | $55.64 |
| Q1 2018 | +16,176 | Add 22.44% | 88,276 | $74.09 |
| Q2 2018 | -17,427 | Reduce 19.74% | 70,849 | $132.18 |
| Q3 2018 | -45,231 | Reduce 63.84% | 25,618 | $161.53 |
| Q4 2018 | -5,437 | Reduce 21.22% | 20,181 | $109.11 |
| Q1 2019 | +1,196 | Add 5.93% | 21,377 | $119.19 |
| Q2 2019 | -4,957 | Reduce 23.19% | 16,420 | $151.95 |
| Q3 2019 | -8,784 | Reduce 53.50% | 7,636 | $75.30 |
| Q4 2019 | -1,754 | Reduce 22.97% | 5,882 | $129.04 |
| Q1 2020 | -1,190 | Reduce 20.23% | 4,692 | $97.83 |
| Q2 2020 | -2,836 | Reduce 60.44% | 1,856 | $160.56 |
| Q3 2020 | +3,158 | Add 170.15% | 5,014 | $140.41 |
| Q4 2020 | -180 | Reduce 3.59% | 4,834 | $170.46 |
| Q1 2021 | -4,834 | Sold Out | 4,834 | $0.00 |
| Q3 2022 | +2,731 | New Buy | 2,731 | $110.58 |
| Q4 2022 | +95 | Add 3.48% | 2,826 | $129.58 |
| Q1 2023 | +5,066 | Add 179.26% | 7,892 | $137.83 |
| Q2 2023 | +1,829 | Add 23.18% | 9,721 | $114.52 |
| Q3 2023 | -1,299 | Reduce 13.36% | 8,422 | $121.22 |
| Q4 2023 | -8,422 | Sold Out | 8,422 | $0.00 |
| Q4 2024 | +1,714 | New Buy | 1,714 | $121.59 |
| Q1 2025 | +3,671 | Add 214.18% | 5,385 | $63.82 |
| Q2 2025 | +120,594 | Add 2239.44% | 125,979 | $17.10 |
| Q3 2025 | +1.28 M | Add 1015.80% | 1.41 M | $18.78 |
Cliff Asness's Sarepta Therapeutics Investment FAQs
Cliff Asness first purchased Sarepta Therapeutics, Inc. (SRPT) in Q4 2012, acquiring 34,647 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Sarepta Therapeutics, Inc. (SRPT) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Sarepta Therapeutics, Inc. (SRPT) was in Q3 2025, adding 1,405,675 shares worth $26.4 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,405,675 shares of Sarepta Therapeutics, Inc. (SRPT), valued at approximately $26.4 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Sarepta Therapeutics, Inc. (SRPT) represents approximately 0.02% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Sarepta Therapeutics, Inc. (SRPT) was 1,405,675 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.